CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 95 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $333 | +66.5% | 11,300 | 0.0% | 0.00% | – |
| Q2 2023 | $200 | +13.0% | 11,300 | 0.0% | 0.00% | – |
| Q1 2023 | $177 | -14.1% | 11,300 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $206 | -99.9% | 11,300 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $214,000 | +8.1% | 11,300 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $198,000 | -7.9% | 11,300 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $215,000 | -22.1% | 11,300 | +9.7% | 0.00% | 0.0% |
| Q4 2021 | $276,000 | +34.6% | 10,300 | +3.0% | 0.00% | 0.0% |
| Q3 2021 | $205,000 | +9.6% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $187,000 | +21.4% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $154,000 | +19.4% | 10,000 | 0.0% | 0.00% | – |
| Q4 2020 | $129,000 | -60.9% | 10,000 | -9.1% | 0.00% | -100.0% |
| Q4 2018 | $330,000 | – | 11,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |